# Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

> **NCT07635056** · PHASE2 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 20 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** CIML-NK Cells

## Key facts

- **NCT ID:** NCT07635056
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2031-06
- **Final completion:** 2031-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635056, "Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07635056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*